A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Author： Chiorean E.   Sweeney Christopher   Youssoufian Hagop   Qin Amy   Dontabhaktuni Aruna   Loizos Nick   Nippgen Johannes   Amato Robert  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.73, Iss.3, 2014-03, pp. : 595-604

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

By Macaulay V. M.   Middleton M. R.   Protheroe A. S.   Tolcher A.   Dieras V.   Sessa C.   Bahleda R.   Blay J.-Y.   LoRusso P.   Mery-Mignard D.   Soria J.-C.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 784-791

Oxford University Press

Access to resources Recommend Favorite

A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

By Arnoletti J.   Frolov A.   Eloubeidi M.   Keene K.   Posey J.   Wood T.   Greeno Edward   Jhala N.   Varadarajulu S.   Russo S.   Christein J.   Oster R.   Buchsbaum D.   Vickers S.  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 891-897

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

By Wheler Jennifer   Janku Filip   Falchook Gerald   Jackson Tiffiny   Fu Siqing   Naing Aung   Tsimberidou Apostalia   Moulder Stacy   Hong David   Yang Hui   Piha-Paul Sarina   Atkins Johnique   Garcia-Manero Guillermo   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 495-501

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

By Wakui Hiroshi   Yamamoto Noboru   Nakamichi Shinji   Tamura Yousuke   Nokihara Hiroshi   Yamada Yasuhide   Tamura Tomohide  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 511-516

Springer Publishing Company

Access to resources Recommend Favorite

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

By Adamson P.   Blaney S.   Widemann B.   Kitchen B.   Murphy R.   Hannah A.   Cropp G.   Patel M.   Gillespie A.   Whitcomb P.   Balis F.M.  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 482-488

Springer Publishing Company

Access to resources Recommend Favorite